Health
STAT+: Pennsylvania Dutch country, tired of waiting for biopharma, builds drug company of its own
Publication: STAT
Author: Jason Mast
Source published: 27/10/2026, 08:30:00 UTC
Briefing created: 27/10/2026, 10:21:20 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 27/10/2026, 08:36:25 UTC.
Briefings
Researchers in Lancaster, Pennsylvania successfully treated a 79-pound calf with a gene therapy for maple syrup urine disease (MSUD), proving the technology works. The treatment was administered to a 5-year-old heifer named Petunia, who was the second of three cows in the study. Despite the success, none of the clinic's patients received the treatment, and the specific gene therapy remains unapproved for clinical trials.
Key points
- Researchers in Lancaster, Pennsylvania successfully treated a 79-pound calf with a gene therapy for maple syrup urine disease (MSUD), proving the technology works.
- The treatment was administered to a 5-year-old heifer named Petunia, who was the second of three cows in the study.
Context
This finding addresses a critical need for a one-time fix for families in the Mennonite community in Lancaster, Pennsylvania, who suffer from MSUD. The study involved three researchers and one cow, with the goal of offering a simple, one-time solution to a life-threatening condition.
Limitations
The evidence is limited to a single cow treated in a clinical setting, not a clinical trial. The specific gene therapy used remains unapproved for clinical trials, and the specific gene therapy used remains unapproved for clinical trials.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 27/10/2026, 10:21:20 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeiacx3rpxg424njwig5dtm25jyiof7ldn5kjiqcgg7hn7dtkurg3kq